Board of directors

Stéphane Boissel is currently Chairman and CEO of SparingVision, a genomic medicine company in ophthalmology. He was previously Executive Vice President of Corporate Strategy at Sangamo Therapeutics, based in San Francisco (USA).

He joined Sangamo Therapeutics on the back of the acquisition by the latter of TxCell SA, a CAR-Treg company he was the CEO of. Stéphane is a seasoned biotech professional with over 25 years of leadership experience across corporate finance, strategy and business development.

Stéphane completed his undergraduate work in management and finance at the University of Lyon and Paris-Dauphine in France and received his MBA from the University of Chicago (IL, USA).

Valérie Moumdjian has over 30 years experience in finance, audit, risk management and corporate governance. After ten years in financial auditing (EY), she led global teams and held senior executive roles in finance, audit and risk management in listed companies (Rhodia, Solvay, Publicis).

Valérie is a lecturer at Sciences Po Executive – IFA (French Institute of Directors), in charge of audit and internal control matters.

She was a member of the Board of Directors of IFACI and Vice-President from 2021 to 2023.

Valérie graduated from a Business School and holds an MBA from Ottawa University (Canada).

Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release platform for therapeutic proteins which was partnered with Bristol Myers Squibb (BMS).

In 2005, Olivier founded Adocia with his father, Gérard Soula, and his brother, Rémi Soula. Olivier has held successively the position of Director of Research and Development, Deputy Chief Executive Officer and then, Chief Executive Officer since 2023. He was instrumental in the signing of 4 major partnerships which represented more than 150 million dollars of revenue with Eli Lilly and with Tonghua Dongbao.
Olivier is co-author of more than 40 patents on protein delivery and has worked for more than 20 years in the field of innovative insulin formulations.

Mads Dall is CEO and owner of Dall & Company, a strategic business development boutique, based in Copenhagen, Denmark, working with clients world-wide mainly within life sciences.

Mads has significant international diabetes industry experience and has operated in US, Europe and Asia with pharma, biotech and med-tech companies in executive, advisory and board positions.

Previous positions include Chief Commercial Officer, Beta Bionics; Executive Vice President, CeQur; Senior Partner, Asia Base; Vice President, Novo Nordisk.

Katya Smirnyagina is Senior Partner for Life Sciences at Oxford Sciences Entreprises. She has two decades of experience in the biotech industry. Katya started her Venture Capital career in 2002 with Alta Partners, a healthcare focused USA fund, followed by Capricorn Partners in Belgium.

She has been a director of a number of public and private companies in Europe and is the past Vice-Chair of InvestEurope. Katya completed her scientific training with a PhD in Cellular & Molecular Biology from the University of Wisconsin-Madison, followed by a postdoc in Microbiology at the Stanford School of Medicine.

Jacky Vonderscher is an experienced leader in the pharmaceutical and biotechnology sector and is currently the President and Chief Executive Officer of ENYO Pharma SA, a company specializing in treatments for impaired kidney function.

With more than 40 years of experience in research and development focused on the development of new therapies and drug delivery systems, he has held several leadership positions at Roche as well as at Sandoz and Novartis in Switzerland and the United States.

Since 2013, he has been advising various biotechnology companies and serves on several boards of directors.

He holds a PhD in Biochemistry from the University of Geneva and an engineering degree in Biological Chemistry from INSA Lyon.